Host modulation therapy in periodontitis

doi:10.12016/j.issn.2096-1456.2019.11.001

Journal of Prevention and Treatment for Stomatological Diseases ›› 2019, Vol. 27 ›› Issue (11): 681-688.DOI: 10.12016/j.issn.2096-1456.2019.11.001

• Expert Commentary • Previous Articles Next Articles

Host modulation therapy in periodontitis

ZHOU Zheng¹(),QI Xia^1,²,YANG Dongru²

^1. Department of Periodontology, School of Dentistry, University of Detroit Mercy, Detroit 48201, USA
^2. Department of Periodontology, Hospital of Stomatology, School of Stomatology, Hebei Medical University, Hebei Key Laboratory of Stomatology, Shijiazhuang 050017, China

Received:2019-02-02 Revised:2019-05-10 Online:2019-11-20 Published:2019-12-03
Contact: Zheng ZHOU

牙周炎的宿主反应调节治疗

周征¹(),齐霞^1,²,杨冬茹²

^1. 美国底特律大学牙学院牙周系,密歇根州底特律（48201）
^2. 河北医科大学口腔医院牙周科·河北医科大学口腔医学院·河北省口腔医学重点实验室,河北石家庄（050017）

通讯作者: 周征
作者简介:周征，美国底特律大学牙学院牙周系教授，研究生课程主任，美国牙周病和种植专业委员会认证专科医师（Diplomate），国际牙医学院院士（美国分部）。美国牙周病学会会员，美国正畸学会会员，美国牙医协会会员。毕业于华西医科大学口腔医学院，获口腔医学学士，口腔正畸学博士学位；在美国佐治亚医学院完成牙周和种植住院医师培训。历任华西口腔医院正畸科副教授，研究生导师，英国利物浦大学牙学院客座教授，美国佐治亚医学院牙周系住院医师及临床指导教师，底特律大学牙学院牙周系副教授。主译《正畸驱动的骨皮质切开术》，参编、参译《中华口腔科学》，《口腔正畸学: 现代原理与技术》，《牙颌面畸形功能矫形》等专著多部。曾主持和参与国家自然科学基金、教育部留学回国基金等项目多项。
基金资助:
河北省政府资助临床医学优秀人才培养和基础课题研究项目(MX2B00049);河北省政府资助专科能力建设和专科带头人培养专科建设项目(361029)

Abstract

Abstract:

Host modulation therapy (HMT), as a treatment concept for periodontitis, aims to modulate the host immune responses during the pathogenesis of periodontitis. Various drugs have been evaluated as HMT, including subdose doxycycline (SDD), nonsteroidal anti-inflammatory drugs (NSAIDs), bisphosphonates, and cytokine receptors, to modify or modulate inflammatory mediators and associated signaling pathways in the immune-inflammatory response, as well as connective tissue breakdown and bone resorption. SDD, a member of the tetracycline drug family, has been reported to improve periodontal treatment outcomes by inhibiting periodontal breakdown through inhibiting MMPs. NSAIDs may suppress periodontal inflammation by reducing cyclooxygenase-2(COX-2) activity. Combined application of SSD and NSAIDs may achieve a better clinical outcome. Recent studies of HMT treatment have focused on the prevention of excessive inflammation by regulating mediators using endogenous lipid mediators. Local administration of bisphosphonates and histone deacetylase inhibitors can inhibit osteoclast activity and regulate bone tissue remodeling. Currently, SSD is approved by the FDA for periodontal treatment. Other drugs, such as COX-2 selective inhibitor, nonsteroidal anti-inflammatory drugs, bisphosphonates, triclosan and iNOS inhibitors, have good application prospects in the prevention and treatment of periodontal disease, and the mechanism and side effects of these drugs remain to be further investigated.

Key words: host modulation therapy, periodontal disease, immune-inflammatory response, tetracyclines, non-steroidal anti-inflammatory drugs, bisphosphonates, cytokines

摘要：

宿主反应调节治疗（host modulation therapy,HMT）是针对牙周炎致病过程中宿主免疫炎症反应而提出,目前作为牙周病的一种治疗方法应用于临床。HMT应用多种不同生物学机制药物如：亚剂量强力霉素,非甾体类抗炎药,双膦酸盐,以及多种组织细胞受体、组蛋白去乙酰基酶抑制剂等对宿主免疫炎症反应、结缔组织破坏和骨组织吸收过程中相关介质及其信号传导通路进行调节,辅助治疗牙周炎。其中,亚剂量强力霉素属于四环素类药物,通过抑制基质金属蛋白酶来抑制牙周组织破坏,辅助牙周基础治疗可显著提高牙周病治疗效果。局部应用非甾体类抗炎药,可选择性抑制牙周病主要炎性介质环氧化酶-2来抑制牙周组织炎症反应。非甾体类抗炎药和四环素类药物联合应用具有更好的治疗效果。通过内源性脂质调控介质防止过度炎症成为近年HMT治疗牙周炎的重要研究方向。局部应用双膦酸盐、组蛋白去乙酰基酶抑制剂可抑制破骨细胞活性,调控骨组织重建。亚剂量强力霉素已通过美国FDA验证,并投入临床应用。其他诸如环氧化酶-2选择性抑制剂、非甾体类抗炎药、双膦酸盐、三氯生、iNOS抑制剂等对牙周病的防治具有良好的应用前景,但其作用机制和副作用等仍需进一步的研究探讨。

关键词: 宿主反应调节治疗, 牙周病, 免疫炎症反应, 四环素类药物, 非甾体抗炎药, 双膦酸盐, 细胞因子

CLC Number:

R781.4

ZHOU Zheng,QI Xia,YANG Dongru. Host modulation therapy in periodontitis[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(11): 681-688.

周征,齐霞,杨冬茹. 牙周炎的宿主反应调节治疗[J]. 口腔疾病防治, 2019, 27(11): 681-688.

Figures/Tables 2

References 50

[1]	Lang NP, Lindhe J . Clinical periodontology and implant dentistry[M]. six edtion. Hoboken: JOHN Wiley & Sons, 2015: 256-266.
[2]	Preshaw PM . Host modulation therapy with anti-inflammatory agents[J]. Periodontol 2000, 2018,76(1):131-149. DOI URL PMID
[3]	Emingil G, Gurkan A, Tervahartiala T , et al. Adjunctive effects of a sub-antimicrobial dose of doxycycline on clinical parameters and potential biomarkers of periodontal tissue catabolism[J]. Dent J, 2019,7(1):9. DOI URL PMID
[4]	Etikala A, Tattan M, Askar H , et al. Effects of NSAIDs on periodontal and dental implant therapy[J]. Compend Contin Educ Dent, 2019,40(2):e1-e9. DOI URL PMID
[5]	Shah N, Nayee S, Pazianas M , et al. Beyond ONJ--a review of the potential uses of bisphosphonates in dentistry[J]. Br Dent J, 2017,222(9):727-730. DOI URL PMID
[6]	Morand D, Davideau JL, Clauss F , et al. Cytokines during periodontal wound healing: potential application for new therapeutic approach[J]. Oral Dis, 2017,23(3):300-311. DOI URL PMID
[7]	Martins M, Jiao Y, Larsson L , et al. Epigenetic modifications of histones in periodontal disease[J]. J Dent Re, 2016,95(2):215-222. DOI URL PMID
[8]	Sapna G, Gokul S, Bagri MK . Matrix metalloproteinases and periodontal diseases[J]. Oral Dis, 2014,20(6):538-550. DOI URL PMID
[9]	Maciejczyk M, Pietrzykowska A, Zalewska A , et al. The significance of matrix metalloproteinases in oral diseases[J]. Adv Clin Exp Med, 2016,25(2):383-390. DOI URL PMID
[10]	Martinho FC, Teixeira FF, Cardoso FG , et al. Clinical investigation of matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases, and matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase complexes and their networks in apical periodontitis[J]. J Endod, 2016,42(7):1082-1088. DOI URL PMID
[11]	Kaur M, Kumar K . Subantimicrobial dose doxycycline in treatment of periodontitis[J]. IJADS, 2017,3(2):41-43. DOI URL PMID
[12]	Golub LM, Elburki MS, Walker C , et al. Non-antibacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases[J]. Int Dent J, 2016,66(3):127-135. DOI URL PMID
[13]	Swamy DN, Sanivarapu S, Moogla S , et al. Chemically modified tetracyclines: the novel host modulating agents[J]. J Indian Soc Periodontol, 2015,19(4):370-374. DOI URL PMID
[14]	Franco C, Patricia HR, Timo S , et al. Matrix metalloproteinases as regulators of periodontal inflammation[J]. Int J Mol Sci, 2017,18(2):e440. DOI URL PMID
[15]	Caton JG, Ciancio S, Blieden T , et al. Subantimicrobial dose doxycycline as an adjunct to scaling and root planing: post-treatment effects[J]. J Clin Periodontol, 2001,28(8):782-789. DOI URL PMID
[16]	Novak MJ, Dawson DR, Magnusson I , et al. Combining host modulation and topical antimicrobial therapy in the management of moderate to severe periodontitis: a randomized multicenter trial[J]. J Periodontol, 2008,79(1):33-41. DOI URL PMID
[17]	Ramamurthy NS, Rifkin BR, Greenwald RA , et al. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines[J]. J Periodontol, 2002,73(7):726-734. DOI URL PMID
[18]	Cazalis J, Tanabe S, Gagnon G , et al. Tetracyclines and chemically modified tetracycline-3(CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood[J]. Inflammation, 2009,32(2):130-137. DOI URL
[19]	Alyousef AA, Divakar DD . Chemically modified tetracyclines an emerging host modulator in chronic periodontitis patients: a randomized, double-blind, placebo-controlled, clinical trial[J]. Microb Pathog, 2017,110:279-284. DOI URL PMID
[20]	Gurgel BCdV, Almeida KT, Peixoto RF , et al. Selective COX-2 inhibitor(meloxicam) and tooth-supporting bone quality. A histomorphometric study in rats[J]. Braz Dent J, 2017,28(2):135-139. DOI URL PMID
[21]	Luchian I, Martu I, Goriuc A , et al. Salivary PGE2 as a potential biochemical marker during orthodontic treatment associated with periodontal disease[J]. Rev Chim, 2016,67(10):2119-2123.
[22]	Oduncuoglu B, Kayar N, Haliloglu S , et al. Effects of a cyclic NSAID regimen on levels of gingival crevicular fluid prostaglandin E2 and interleukin-1β: a 6-month randomized controlled clinical trial[J]. Niger J Clin Pract, 2018,21(5):658-666. DOI URL PMID
[23]	Srinivas M, Medaiah S, Girish S , et al. The effect of ketoprofen in chronic periodontitis: a clinical double-blind study[J]. J Indian Soc Periodontol, 2011,15(3):255-259. DOI URL PMID
[24]	Kirschneck C, Meier M, Bauer K , et al. Meloxicam medication reduces orthodontically induced dental root resorption and tooth movement velocity: a combined in vivo and in vitro study of dental-periodontal cells and tissue[J]. Cell Tissue Res, 2017,368(1):61-78. DOI URL PMID
[25]	Azoubel M, Menezes A, Bezerra D , et al. Comparison of etoricoxib and indomethacin for the treatment of experimental periodontitis in rats[J]. Braz J Med Biol Res, 2007,40(1):117-125. DOI URL PMID
[26]	Lee HM, Ciancio SG, Tuter G , et al. Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug[J]. J Periodontol, 2004,75(3):453-463. DOI URL PMID
[27]	Osorio MP, Satheesh E, Lee CT . Specialized pro-resolving lipid mediators in experimental periodontitis: a systematic review[J]. Oral Dis, 2018,9(1):1-12. DOI URL PMID
[28]	Van Dyke T, Hasturk H, Kantarci A , et al. Proresolving nanomedicines activate bone regeneration in periodontitis[J]. J Dent Res, 2015,94(1):148-156. DOI URL PMID
[29]	Lee CT, Teles R, Kantarci A , et al. Resolvin E1 reverses experimental periodontitis and dysbiosis[J]. J Immunol, 2016,197(7):2796-2806. DOI URL PMID
[30]	El-Sharkawy H, Aboelsaad N, Eliwa M , et al. Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 fatty acids and low-dose aspirin[J]. J Periodontol, 2010,81(11):1635-1643. DOI URL PMID
[31]	Fredman G, Oh SF, Ayilavarapu S , et al. Impaired phagocytosis in localized aggressive periodontitis: rescue by resolvin E1[J]. PLoS One, 2011,6(9):e24422. DOI URL PMID
[32]	Trombelli L, Farina R . Efficacy of triclosan-based toothpastes in the prevention and treatment of plaque-induced periodontal and peri-implant diseases[J]. Minerva Stomatol, 2013,62(3):71-88. URL PMID
[33]	Pancer BA, Kott D, Sugai JV , et al. Effects of triclosan on host response and microbial biomarkers during experimental gingivitis[J]. J Clin Periodontol, 2016,43(5):435-444. DOI URL PMID
[34]	Martin TJ, Sims NA . RANKL/OPG: critical role in bone physiology[J]. Rev Endocr Metab Disord, 2015,16(2):131-139. DOI URL PMID
[35]	Meric P, Gurlek O . Periodontal diseases/treatment and bisphosphonates[J]. Curr Oral Health Rep, 2018,5(1):1-6. DOI URL PMID
[36]	Russell R, Whyte M, Greenberg C , et al. The relationship between the chemistry and biological activity of the bisphosphonates[J]. Scott Med J, 2015,60(3):115-120. DOI URL PMID
[37]	Kruger TB, Herlofson BB, Landin MA , et al. Alendronate alters osteoblast activities[J]. Acta Odontol Scand, 2016,74(7):550-557. DOI URL PMID
[38]	Polymeri AA, Kodovazenitis GJ, Polymeris AD , et al. Bisphosphonates: clinical applications and adverse events in dentistry[J]. Oral Health Prev Dent, 2015,13(4):289-299. DOI URL PMID
[39]	Martins CA, Leyhausen G, Volk J , et al. Effects of alendronate on osteoclast formation and activity in vitro[J]. J Endod, 2015,41(1):45-49. DOI URL PMID
[40]	Hiltunen AK, Skogman ME, Rosenqvist K , et al. Bioactive glass combined with bisphosphonates provides protection against biofilms formed by the periodontal pathogen Aggregatibacter actinomycetemcomitans[J]. Int J Pharm, 2016,501(1/2):211-220. DOI URL PMID
[41]	Furlaneto FA, Nunes NL, Oliveira Filho IL , et al. Effects of locally administered tiludronic acid on experimental periodontitis in rats[J]. J Periodontol, 2014,85(9):1291-1301. DOI URL PMID
[42]	Abtahi J, Henefalk G, Aspenberg P . Randomised trial of bisphosphonate-coated dental implants: radiographic follow-up after five years of loading[J]. Int J Oral Maxillofac Surg, 2016,45(12):1564-1569. DOI URL PMID
[43]	Pradeep A, Kumari M, Rao NS , et al. 1% alendronate gel as local drug delivery in the treatment of class Ⅱfurcation defects: a randomized controlled clinical trial[J]. J Periodontol, 2013,84(3):307-315. DOI URL PMID
[44]	Cantley MD, Bartold PM, Fairlie DP , et al. Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases[J]. J Pharm Pharmacol, 2012,64(6):763-774. DOI URL PMID
[45]	Kim HN, Ha H, Lee JH , et al. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL[J]. Eur J Pharmacol, 2009,623(1):22-29. DOI URL
[46]	Oates T, Graves D, Cochran D . Clinical, radiographic and biochemical assessment of IL-1/TNF-α antagonist inhibition of bone loss in experimental periodontitis[J]. J Clin Periodontol, 2002,29(2):137-143. DOI URL PMID
[47]	Garlet G, Cardoso C, Campanelli A , et al. The dual role of p55 tumour necrosis factor-α receptor in Actinobacillus actinomycetemcomitans-induced experimental periodontitis: host protection and tissue destruction[J]. Clin Exp Immunol, 2007,147(1):128-138. DOI URL PMID
[48]	Chang PC, Tsai SC, Chong LY , et al. N-Phenacylthiazolium bromide inhibits the advanced glycation end product(age)--age receptor axis to modulate experimental periodontitis in rats[J]. J Periodontol, 2014,85(7):e268-e276. DOI URL PMID
[49]	Scarel-Caminaga RM, Cera FF, Pigossi SC , et al. Inducible nitric oxide synthase polymorphisms and nitric oxide levels in individuals with chronic periodontitis[J]. Int J Mol Sci, 2017,18(6):1-11. DOI URL PMID
[50]	Adachi K, Miyajima SI, Nakamura N , et al. Role of poly(ADP-ribose) polymerase activation in the pathogenesis of periodontitis in diabetes[J]. J Clin Periodontol, 2017,44(10):971-980. DOI URL PMID

Host modulation therapy in periodontitis

牙周炎的宿主反应调节治疗

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 50

Related Articles 15

Recommended Articles

Metrics

[1]	YAN Xingquan,NAN Xinrong,ZHANG Zejun,ZHANG Qi. Outcomes of surgical treatment of 29 patients with stages Ⅱ-Ⅲ bisphosphonate-related osteonecrosis of the jaw [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2021, 29(6): 395-399.
[2]	GU Wenjia,LU Haixia,ZHANG Yu,FENG Xiping. Research progress on the study of the relationship between periodontitis and cancers of the digestive system [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2021, 29(5): 346-350.
[3]	YANG Ting,HUANG Shiguang. The interaction between Cyclophilin A and CD147 and its clinical significance in periodontal diseases [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2021, 29(3): 189-193.
[4]	TANG Jing,YE Changchang,XIA Zhongyi,WU Wanhong,HUANG Ping,WU Yafei. Investigation on the influence of periodontal disease in gestation on small for gestational age [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2020, 28(5): 307-312.
[5]	XIA Fengjuan,SHEN Xiaoqing. The relationship between maternal periodontal disease and preterm low birth weight [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(8): 541-544.
[6]	Peng ZHOU,Jianping TAN,Dan WANG,Ming TANG. The oral health status of senile dementia patients: a systematic review [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(7): 457-463.
[7]	CHENG Guoping,DING Yi,GUO Shujuan. Research progress on liposomes and periodontal disease [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(10): 658-661.
[8]	Yang LIU, Yueping ZHAO. Research advances in the correlations between periodontal disease and autophagy [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2018, 26(4): 268-272.
[9]	Yuhong XIA, Huimin YU, Di ZHANG, Chunxian WANG. Research progress in influence of periodontal disease on dental implantation [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2018, 26(2): 120-123.
[10]	YE Huiming,ZHU Xiaobin,ZHANG Yangqing,ZHOU Qiaoyi,XU Lin,ZENG Yinghuai. Study on the second personalized chair-side education to change the knowledge, attitude, and practice of patients with periodontitis [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2018, 26(12): 795-801.
[11]	Ying ZHAO,Xiaoping LIN. A systematic analysis of the correlation between periodontal disease and rheumatoid arthritis [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2018, 26(10): 663-668.
[12]	Dandan HUANG. Effect of orthodontic treatment on alveolar bone density and epidermal growth factor expression in patients with periodontal disease [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2017, 25(6): 389-393.
[13]	Yuan-yuan LUO, Zhong-juan TAN, Yue-ping ZHAO. Progress in relationship between leptin and periodontitis [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2017, 25(5): 331-335.
[14]	Jie LIU, Hua TANG. The establishment of a bisphosphonate-related osteonecrosis of the jaw rat model [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2017, 25(2): 133-136.
[15]	ZHAO Jing,LI Xin-yue,SHI Dong. Clinical application of alternative materials for the treatment of gingival retraction with subepithelial connective tissue [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2016, 24(9): 554-557.